Balancing Treatment Efficacy and Quality of Life in Metastatic Triple-Negative Breast Cancer

This video was supported by Gilead Sciences, Inc., but editorially independently created by the Oncology Nursing News team.

NP Theresa Stukus and NP Nelli Zafman discuss long-term management considerations for a patient with metastatic triple-negative breast cancer (mTNBC) who is experiencing ongoing treatment-related toxicities while maintaining disease control on frontline therapy. Using the clinical scenario, the faculty explore strategies for balancing sustained treatment efficacy with preservation of quality of life through individualized dose modifications, temporary treatment interruptions, and continuous reassessment of patient goals. NP Zafman emphasizes that cumulative toxicities should be addressed proactively to help patients remain on therapy while minimizing the impact on daily activities and family responsibilities. The speakers also discuss the importance of setting realistic expectations and reassuring patients that dose reductions or planned treatment breaks can be appropriate components of care when clinically indicated. Throughout the discussion, NP Stukus and NP Zafman reinforce that ongoing communication, shared decision-making, and individualized supportive care are essential to optimizing long-term outcomes and maintaining quality of life for patients with metastatic triple-negative breast cancer.